153 related articles for article (PubMed ID: 18337611)
1. Cetuximab for colorectal cancer.
Yang F; Fu D; Ni Q
N Engl J Med; 2008 Mar; 358(11):1195; author reply 1196-7. PubMed ID: 18337611
[No Abstract] [Full Text] [Related]
2. Cetuximab for colorectal cancer.
Fraggetta F; Pelosi G
N Engl J Med; 2008 Mar; 358(11):1196; author reply 1196-7. PubMed ID: 18340663
[No Abstract] [Full Text] [Related]
3. Cetuximab for colorectal cancer.
Roila F; Garassino MC; Mantica C
N Engl J Med; 2008 Mar; 358(11):1196; author reply 1196-7. PubMed ID: 18340662
[No Abstract] [Full Text] [Related]
4. Cetuximab for colorectal cancer.
van der Spek E; Sonke GS
N Engl J Med; 2008 Mar; 358(11):1196; author reply 1196-7. PubMed ID: 18340661
[No Abstract] [Full Text] [Related]
5. Clinical use of monoclonal antibodies to the epidermal growth factor receptor in colorectal cancer.
Burtness B
Oncology (Williston Park); 2007 Jul; 21(8):964-70; discussion 970, 974, 976-7. PubMed ID: 17715697
[TBL] [Abstract][Full Text] [Related]
6. Targeting EGFR in colorectal cancer.
Messersmith WA; Ahnen DJ
N Engl J Med; 2008 Oct; 359(17):1834-6. PubMed ID: 18946069
[No Abstract] [Full Text] [Related]
7. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
Jean GW; Shah SR
Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
[TBL] [Abstract][Full Text] [Related]
8. To give or not to give anti-epidermal growth factor receptor (EGFR) monoclonal antibodies to patients with KRAS G13D mutation in advanced colorectal cancer.
Kim R; Kubal T
Clin Colorectal Cancer; 2012 Jun; 11(2):85-7. PubMed ID: 22169039
[No Abstract] [Full Text] [Related]
9. PET detection of epidermal growth factor receptor in colorectal cancer: a real predictor of response to cetuximab treatment?
Pantaleo MA; Fanti S; Lollini PL; Boschi S; Biasco G
Eur J Nucl Med Mol Imaging; 2007 Sep; 34(9):1510-1. PubMed ID: 17447062
[No Abstract] [Full Text] [Related]
10. Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab.
You B; Chen EX
J Clin Pharmacol; 2012 Feb; 52(2):128-55. PubMed ID: 21427284
[TBL] [Abstract][Full Text] [Related]
11. [Mutation of EGFR signaling pathway and therapy for metastatic colorectal cancer].
Nozawa K; Watanabe T
Gan To Kagaku Ryoho; 2010 May; 37(5):791-4. PubMed ID: 20495308
[TBL] [Abstract][Full Text] [Related]
12. Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer.
Hebbar M; Wacrenier A; Desauw C; Romano O; Cattan S; Triboulet JP; Pruvot FR
Anticancer Drugs; 2006 Aug; 17(7):855-7. PubMed ID: 16926635
[TBL] [Abstract][Full Text] [Related]
13. Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach?
Fakih M
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1471-80. PubMed ID: 18759698
[TBL] [Abstract][Full Text] [Related]
14. Panitumumab (Vectibix) for metastatic colorectal cancer.
Med Lett Drugs Ther; 2007 Apr; 49(1259):35-6. PubMed ID: 17450113
[No Abstract] [Full Text] [Related]
15. Introduction: Emerging therapies with epidermal growth factor receptor-targeted agents in colorectal cancer.
Chu E
Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S60-1. PubMed ID: 16336750
[No Abstract] [Full Text] [Related]
16. Cetuximab.
Graham J; Muhsin M; Kirkpatrick P
Nat Rev Drug Discov; 2004 Jul; 3(7):549-50. PubMed ID: 15272498
[No Abstract] [Full Text] [Related]
17. Anti-epidermal growth factor receptor antibodies in the treatment of metastatic colorectal cancer.
Lee D
Clin Colorectal Cancer; 2004 Sep; 4(3):159-62. PubMed ID: 15377399
[No Abstract] [Full Text] [Related]
18. Epidermal growth factor receptor expression discrepancies in metastatic colorectal cancer patients treated with cetuximab plus irinotecan-based chemotherapy refractory to irinotecan and oxaliplatin.
Han HS; Chang HJ; Hong YS; Kim SY; Lee KS; Jung KH
Dis Colon Rectum; 2009 Jun; 52(6):1144-51; discussion 1152-3. PubMed ID: 19581859
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab vs EGFR antibodies in metastatic colorectal cancer.
Venook AP
Clin Adv Hematol Oncol; 2015 Feb; 13(2):90-2. PubMed ID: 25774477
[No Abstract] [Full Text] [Related]
20. Is immunohistochemistry for epidermal growth factor receptor expression a poor predictor of response to epidermal growth factor receptor-targeted therapy?
Younes M
J Clin Oncol; 2005 Feb; 23(4):923; author reply 923-4. PubMed ID: 15681544
[No Abstract] [Full Text] [Related]
[Next] [New Search]
